BACKGROUND: Hepatitis E causes a significant burden of disease in developing countries and has recently been increasingly recognized in developed countries. Comparing population anti-hepatitis E virus (HEV) seroprevalence across populations has been difficult. OBJECTIVES: The aim of this study was to compare the anti-HEV IgG seroprevalence in both adults and children in three hyper-endemic areas (Nepal, Bangladesh and southwest France) using a sensitive, commercial anti-HEV IgG assay. STUDY DESIGN: Serum or plasma from adults and children in Nepal (n=498), Bangladesh (n=1,009) and Southwest France (n=1031) were tested for anti-HEV IgG using the Wantai assay. RESULTS: After age-standardization, anti-HEV IgG seroprevalence was 47.1%, 49.8% and 34.0% in Nepal, Bangladesh and southwest France, respectively. There was no difference in seroprevalence by gender in any of the countries. A paucity of infections in children 1-10 years-old was consistently observed (less than 15%) at all 3 locations. CONCLUSIONS: Surprisingly similar high rates of anti-HEV antibodies were detected using a common, sensitive assay. Despite differences in the epidemiology and circulating genotype of HEV in Nepal, Bangladesh and southwest France, this study found more similarities in population seroprevalence than expected.
BACKGROUND:Hepatitis E causes a significant burden of disease in developing countries and has recently been increasingly recognized in developed countries. Comparing population anti-hepatitis E virus (HEV) seroprevalence across populations has been difficult. OBJECTIVES: The aim of this study was to compare the anti-HEV IgG seroprevalence in both adults and children in three hyper-endemic areas (Nepal, Bangladesh and southwest France) using a sensitive, commercial anti-HEV IgG assay. STUDY DESIGN: Serum or plasma from adults and children in Nepal (n=498), Bangladesh (n=1,009) and Southwest France (n=1031) were tested for anti-HEV IgG using the Wantai assay. RESULTS: After age-standardization, anti-HEV IgG seroprevalence was 47.1%, 49.8% and 34.0% in Nepal, Bangladesh and southwest France, respectively. There was no difference in seroprevalence by gender in any of the countries. A paucity of infections in children 1-10 years-old was consistently observed (less than 15%) at all 3 locations. CONCLUSIONS: Surprisingly similar high rates of anti-HEV antibodies were detected using a common, sensitive assay. Despite differences in the epidemiology and circulating genotype of HEV in Nepal, Bangladesh and southwest France, this study found more similarities in population seroprevalence than expected.
Authors: Ashish C Shrestha; Robert L P Flower; Clive R Seed; Manita Rajkarnikar; Shrawan K Shrestha; Uru Thapa; Veronica C Hoad; Helen M Faddy Journal: BMC Infect Dis Date: 2016-11-25 Impact factor: 3.090
Authors: Pilar Clemente-Casares; Carlota Ramos-Romero; Eugenio Ramirez-Gonzalez; Antonio Mas Journal: Biomed Res Int Date: 2016-12-14 Impact factor: 3.411
Authors: Montserrat Elemi García-Hernández; Mayra Cruz-Rivera; José Iván Sánchez-Betancourt; Oscar Rico-Chávez; Arely Vergara-Castañeda; María E Trujillo; Rosa Elena Sarmiento-Silva Journal: BMC Vet Res Date: 2017-09-21 Impact factor: 2.741
Authors: Andrew S Azman; Malika Bouhenia; Anita S Iyer; John Rumunu; Richard Lino Laku; Joseph F Wamala; Isabel Rodriguez-Barraquer; Justin Lessler; Etienne Gignoux; Francisco J Luquero; Daniel T Leung; Emily S Gurley; Iza Ciglenecki Journal: Am J Trop Med Hyg Date: 2017-06 Impact factor: 2.345
Authors: Richie G Madden; Sebastian Wallace; Mark Sonderup; Stephen Korsman; Tawanda Chivese; Bronwyn Gavine; Aniefiok Edem; Roxy Govender; Nathan English; Christy Kaiyamo; Odelia Lutchman; Annemiek A van der Eijk; Suzan D Pas; Glynn W Webb; Joanne Palmer; Elizabeth Goddard; Sean Wasserman; Harry R Dalton; C Wendy Spearman Journal: World J Gastroenterol Date: 2016-11-28 Impact factor: 5.742
Authors: Juliana Gil Melgaço; Noemi Rovaris Gardinali; Vinicius da Motta de Mello; Mariana Leal; Lia Laura Lewis-Ximenez; Marcelo Alves Pinto Journal: Biomed Res Int Date: 2018-01-09 Impact factor: 3.411